Belgium Medical Inc.: To Attend ANMA 23rd Annual Convention, Las Vegas, July 30-August 1, 2004

2004-07-28 13:10 ET - News Release

VANCOUVER, British Columbia -- (Business Wire) -- July 28, 2004

     Meridian Co., Ltd. ("Meridian") (OTCBB:MRDAF), is 
pleased to announce that its subsidiary, Belgium Medical Inc. ("MMI" 
or "the Company") will be attending the American Naturopathic Medical 
Association's ("ANMA") 23rd annual convention in Las Vegas to promote 
one of its feature medical diagnostic products: the Digital Pulse 
Analyzer ("DPA"). The DPA detects early vascular changes - a major 
risk for cardiovascular disease, the #1 killer in the United States 
with an estimated economic cost of approximately $298 billion.

     More about: ANMA

     Founded in 1981, ANMA is dedicated to exploring new frontiers of 
mind, body, medicine and health. ANMA is aimed not only at 
individuals with Doctor of Naturopathy (N.D.) or Doctor of 
Naturopathic Medicine (N.M.D.), but includes a wide variety of other 
health care fields. With approximately 4,000 members in the United 
States, Canada, and fourteen foreign countries ANMA is the largest 
professional naturopathic medical association in America today. ANMA 
is recognized by the World Organization for Alternative Medicine as 
the primary organization representing naturopathic medicine in the 
United States.

     The Company will join presenters from around the world to share 
their knowledge and experience in their respective medical field. 
This offers the Company the opportunity to form valuable strategic 
relationships within the industry. The event is being held at the 
Riviera Hotel & Casino in Las Vegas, with activities beginning Friday 
morning at 8:00 a.m. and ending at Sunday at 3:00 p.m. The Company 
will be showcasing its product at Booth 418, with a company 
representative giving a special one-hour speaking engagement on the 
features and benefits of the DPA.

     More about: Digital Pulse Analyzer ("DPA")

     The "DPA" accurately measures the elasticity of small and large 
arteries and provides health care practitioners with critical 
information regarding arterial aging. This FDA approved device is 
inexpensive, non-invasive, and can provide results in minutes. 
Accumulating evidence suggests that abnormalities in the pulsatile 
characteristics of arteries occur early in the disease process 
associated with increased cardiovascular risk, and can be favorably 
modified by therapeutic interventions.

     The Company feels that use of the "DPA" can help caregivers 
reduce cardiovascular disease in their patient populations through 
early detection and prevention, and ultimately assist to decrease the 
associated financial costs placed on the health care industry.

     ABOUT MERIDIAN

     Meridian is an established leader in the research/development, 
manufacturing, and sales of integrative medical diagnostic equipment. 
The company sells its products and equipment to a wide array of 
customers in the global health care industry. The company presently 
holds a total of 18 worldwide patents on its technology, and has 
received FDA, as well as other international regulatory approvals for 
many of it's products.

     Meridian is committed to the ongoing global research and 
advancement of integrative medical products that contribute to the 
better health of humanity.

Contacts:

Meridian Co., Ltd.
Debbie Williams
President
(604) 926-3495
Website (Korean): www.meridian.co.kr
Website (North America): meridianmedical.ca